BGI
RARE icon

B Group Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

B Group Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-67,600
Closed -$2.46M – 21
2025
Q2 		$2.46M Buy
67,600
+30,000
+80% +$1.08M 1.89% 13
2025
Q1 		$1.36M Buy
37,600
+8,100
+27% +$337K 1.17% 13
2024
Q4 		$1.24M Buy
+29,500
New +$1.46M 0.76% 11

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

B Group Inc's RARE Position: Q1 2026 in Review

B Group Inc held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 135,000 shares worth $2.83M. The position accounts for 2.1% of the portfolio, ranked #16.

B Group Inc first reported a position in RARE in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.06M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • B Group Inc held 135,000 shares of Ultragenyx Pharmaceutical worth $2.83M as of Q1 2026.
  • B Group Inc left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
  • Ultragenyx Pharmaceutical made up 2.1% of B Group Inc's portfolio in Q1 2026, its #16 holding.
  • B Group Inc first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • B Group Inc's Ultragenyx Pharmaceutical position peaked at $4.06M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.